Cleveland Biolabs’ CBLB502 for Reducing the Risk of Death Following Total Body Irradiation During or After a Radiation …

Published July 23, 2010

Cleveland Biolabs’ CBLB502 for Reducing the Risk of Death Following Total Body Irradiation During or After a Radiation …
BUFFALO, NY–(Marketwire – 07/22/10) – Cleveland BioLabs, Inc. (NASDAQ: CBLI – News ) today announced that CBLB502, a drug under development for the treatment of Acute Radiation Syndrome (ARS), has been granted Fast Track status by the U.S. Food and Drug Administration (FDA). The Fast Track program is designed to expedite the review of investigational drugs for the treatment of patients with …
Read more on Marketwire via Yahoo! Finance

Money Needed for Human Testing of Breast Cancer Vaccine
By Cameron Glover – A researcher who successfully tested a vaccine that prevented breast cancer in mice is having a difficult time getting someone to pay for the next round of tests in humans.
Read more on Kansas City InfoZine